264 related articles for article (PubMed ID: 20014888)
21. Medical treatment of epithelial ovarian cancer.
González-Martín AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
[TBL] [Abstract][Full Text] [Related]
22. Therapy for recurrent ovarian cancer.
Kuhn WC
Curr Womens Health Rep; 2003 Feb; 3(1):33-8. PubMed ID: 12521548
[TBL] [Abstract][Full Text] [Related]
23. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
24. Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP; Schilder RJ
Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
[TBL] [Abstract][Full Text] [Related]
25. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
26. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
27. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
[TBL] [Abstract][Full Text] [Related]
28. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
Camci C; Sevinc A; Aslan Y; Kalender ME; Buyukberber S
Cancer Chemother Pharmacol; 2009 Mar; 63(4):745-8. PubMed ID: 18504578
[TBL] [Abstract][Full Text] [Related]
29. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Selvaggi L; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Marforio G; Ballardini M; Lombardi AV; Sorio R; Tumolo S; Costa B; Magni G; Perrone F; Favalli G;
Oncology; 2006; 71(5-6):320-6. PubMed ID: 17878745
[TBL] [Abstract][Full Text] [Related]
30. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.
Karam AK; Santillan A; Bristow RE; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Feb; 104(2):377-80. PubMed ID: 17014899
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy in epithelial ovarian cancer.
Wang J; Li AJ; Karlan BY
Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979
[TBL] [Abstract][Full Text] [Related]
32. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
33. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
[TBL] [Abstract][Full Text] [Related]
34. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
Markman M
Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
[No Abstract] [Full Text] [Related]
35. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
36. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
37. Second-line treatment of first relapse recurrent ovarian cancer.
Chua TC; Liauw W; Robertson G; Morris DL
Aust N Z J Obstet Gynaecol; 2010 Oct; 50(5):465-71. PubMed ID: 21039382
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of ovarian cancer].
Cianti C
Clin Ter; 2002; 153(2):135-44. PubMed ID: 12078339
[TBL] [Abstract][Full Text] [Related]
39. Treatment of platinum-resistant recurrent ovarian cancer using a "predictive molecule targeted routine chemotherapy" system.
Zhao XD; Wei FH; Zhang Y; He SR; Yang L
Chin Med J (Engl); 2009 Dec; 122(23):2856-60. PubMed ID: 20092790
[TBL] [Abstract][Full Text] [Related]
40. Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study.
Fotopoulou C; Cho CH; Kraetschell R; Gellermann J; Wust P; Lichtenegger W; Sehouli J
Int J Hyperthermia; 2010; 26(2):118-26. PubMed ID: 20146566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]